|Mr. Krish S. Krishnan||Chairman, Pres & CEO||704.99k||N/A||1965|
|Ms. Suma M. Krishnan||Founder, COO & Director||495.44k||N/A||1965|
|Mr. Antony A. Riley||Chief Financial Officer||124.27k||N/A||1967|
|Ms. Gloria Lin||Accounting Mang.||N/A||N/A||N/A|
|Ms. Katherine Tuminello||HR & Office Mang.||N/A||N/A||N/A|
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.